Clinical Data Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis PharmaTimesLead candidate ETD001 delivers significant lung function improvementRespiratoryRead full story pharminent May 12, 2026 (Last updated: May 16, 2026) PharmaTimes Lead candidate ETD001 delivers significant lung function improvement Respiratory Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Cellular Intelligence scoops up Novo’s Parkinson’s therapyNext: 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) Related Stories Clinical Data ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma pharminent June 2, 2026 Clinical Data ASCO26: In vivo oncology approaches continue to show promise pharminent June 2, 2026 Clinical Data ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come pharminent June 2, 2026
